15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Precision BioSciences Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $20.00 to $60.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $36.67 sits 412% above the current $7.17. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.65 next quarter toward $-1.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Precision BioSciences Inc.
As of Jul, 3 of 3 firms rate DTIL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DTIL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.65
Range $-0.72 – $-0.51 · 3 analysts · -65% YoY
Next period, 3 analysts expect Precision BioSciences Inc to earn $-0.65 a share (range $-0.72 – $-0.51), versus $-1.84 a year earlier. Full-year consensus is $-2.49, growing to $-1.89 the year after.
REVENUE · NEXT QUARTER
$1.8M
Range $0 – $3.3M · 3 analysts · +13438% YoY
Revenue is expected to reach $1.8M (range $0 – $3.3M), +13438.5% year-over-year. Full-year consensus is $18.8M, rising to $12.5M next year.
Top analysts covering Precision BioSciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DTIL.
#1
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$60.00+737.4% to target
Overall win rate
35%
+ Follow
#2
Catherine Novack
Jones Trading
Buy
$30.00+318.7% to target
Coverage
—
+ Follow
#3
CN
Catherine Novack
JonesTrading
Buy
$30.00+318.7% to target
Coverage
—
+ Follow
#4
KB
Kostas Biliouris
BMO Capital
Buy
$34.00+374.5% to target
Coverage
—
+ Follow
DTIL stock forecast FAQ
What is DTIL's average 12-month price target?+
The 3 analysts with a live target average $36.67 for Precision BioSciences Inc over the next 12 months, ranging from a $60.00 high to a $20.00 low.
Is DTIL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DTIL?+
The Street-high target is $60.00 (HC Wainwright & Co.), and the Street-low is $20.00 (Oppenheimer). The average of all 3 active targets is $36.67.
How many Wall Street analysts cover DTIL?+
3 analysts have an active rating on Precision BioSciences Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering DTIL?+
Among analysts who currently cover DTIL, Patrick R. Trucchio of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #203). Their current call is Buy with a $60.00 target.
What is Precision BioSciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.65 per share (range $-0.72 – $-0.51) across 3 analysts. Full-year EPS is projected at $-2.49, rising to $-1.89 the following year.
How much revenue is Precision BioSciences Inc expected to report next quarter?+
Consensus revenue is $1.8M (range $0 – $3.3M). Full-year revenue is projected at $18.8M, growing to $12.5M next year.
Have analysts been upgrading or downgrading DTIL lately?+
As of Jul, 3 of 3 firms rate DTIL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DTIL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Oppenheimer
